Рекормон is used to address several clinical situations by working with the body’s natural processes to help maintain red blood cell levels. This medication is primarily prescribed to help manage anemia that results from chronic kidney disease or certain chemotherapy treatments.

Main Therapeutic Uses

The primary clinical scenarios where Рекормон is indicated include managing symptomatic anemia associated with chronic renal failure (in patients on dialysis and those not yet undergoing dialysis) and addressing anemia in individuals receiving myelosuppressive chemotherapy for non-myeloid malignancies. It may also be considered for certain surgical patients to assist in lowering the potential for requiring an allogeneic blood transfusion.

Quick Fact: Relief for Fatigue

By assisting red blood cell production, the treatment may help reduce the severity of common anemia symptoms such as fatigue and general weakness, which may support the patient's ability to engage in daily activity.

Who Can and Cannot Use Рекормон?

Eligibility for Рекормон (Epoetin Beta) is strictly determined by regulatory labeling, covering specific patient populations and absolute exclusions.

---

Contraindicated Populations (Cannot Use)

The medicine is absolutely prohibited (contraindicated) for use in patients with:

• Uncontrolled Hypertension: Poorly controlled high blood pressure.
• Hypersensitivity: A known history of allergic reaction to Epoetin Beta or its components.
• Pure Red Cell Aplasia (PRCA): A history of PRCA following prior treatment with any erythropoietin product.

Additionally, for the autologous blood donation indication, use is contraindicated in patients with recent cardiovascular events, such as a myocardial infarction or stroke, or those at high risk of deep vein thrombosis.

---

Approved Populations and Restrictions

Рекормон is officially approved for adult and pediatric patients with symptomatic anemia due to chronic renal failure. It is also approved for adult patients with chemotherapy-induced anemia in non-myeloid malignancies and for the prevention of anemia in specific premature infants.

Use requires that iron deficiency and all other causes of anemia be corrected or excluded prior to starting treatment. The indication for chemotherapy-induced anemia is not approved for children.

Interactions with other medicines and products

The official regulatory profile for Epoetin Beta (Рекормон) differs from that of typical small-molecule drugs, as it is a recombinant protein and is not documented to be metabolized by the Cytochrome P450 (CYP) enzyme system or major drug transporters.

Pharmacokinetic and Metabolic Profile

No clinically significant pharmacokinetic interactions have been formally documented where Epoetin Beta alters the plasma concentrations of other co-administered medicinal products, nor are there known substances that modify its systemic exposure (AUC or C max). The label indicates an absence of documented interactions mediated by CYP enzymes or drug transport proteins.

Required Concomitant Agents and Procedural Constraints

Interaction Type	Interacting Substance/Condition	Official Regulatory Restriction/Requirement
Pharmacodynamic Dependency	Iron, Folic Acid, Vitamin B12	Effectiveness is formally dependent upon adequate stores of these hematinics; supplementation is often required to support the medicine's primary effect.
Contextual Interaction	Heparin	Use in hemodialysis patients may necessitate an increase in the dose of Heparin to manage the risk of clotting in the vascular access.
Administration Incompatibility	All other liquid medicinal products	The solution must not be mixed with any other medicines due to a documented absence of compatibility studies.

No drug-drug combinations are formally classified as contraindicated based on a specific interaction pattern in the official prescribing information. The interaction structure is defined by the absolute necessity for sufficient hematinic substrate and a non-mixing rule for administration.

How Рекормон Works

Рекормон works by acting as a functional agonist of the natural hormone, erythropoietin (EPO), which modulates the rate of red blood cell production entirely within the bone marrow's hematopoietic tissue.

Targeted Receptor Activation

The drug specifically engages the Erythropoietin Receptor (EPOR) found on the surface of erythroid progenitor cells. This binding event initiates the essential molecular step for cell maturation and growth.

Intracellular Signal Modulation

Once the receptor is activated, an intracellular signaling cascade, specifically the JAK2/STAT5 pathway, is triggered. This pathway communicates signals that override the cell’s natural tendency toward programmed death (apoptosis), thereby increasing the survival and proliferation of red blood cell precursors, leading to their differentiation into mature cells.

Consequence for Systemic Oxygen Transport

This molecular and cellular cascade results in an increase in the total number of circulating red blood cells and the amount of hemoglobin. This physiological outcome directly leads to a higher systemic capacity for oxygen transport.

Official Administration and Dosing Guidelines

Рекормон (Epoetin Beta) is an injectable prescription medicine whose use is governed by official prescribing information and approved labels.

---

Approved Administration Routes and Preparation

Administration Route	Recommended Use Context	Preparation Requirement
Subcutaneous (SC) Injection	Preferred for patients who are not receiving chronic haemodialysis, including most children and patients receiving chemotherapy.	The solution must be visually clear and colorless. It must not be vigorously shaken or mixed with other medicinal products.
Intravenous (IV) Injection	Recommended for adult patients undergoing haemodialysis, typically injected via the arterio-venous fistula at the end of the dialysis session.	The IV injection should be administered slowly, generally over approximately two minutes.

---

Dosing and Adjustment Protocol

The dosage for Рекормон is measured in International Units (IU) and is divided into a Correction Phase (initial treatment) and a Maintenance Phase (long-term use). The dose is not fixed but is titrated based on frequent monitoring of the patient's haemoglobin (Hb) levels to ensure the level remains within the target range (e.g., 10 to 12 g/dl).

• Starting Dose: Initial doses for Chronic Kidney Disease (CKD) are typically calculated based on IU per kilogram of body weight (e.g., 60 IU/kg/week SC or 40 IU/kg three times per week IV for adults).
• Frequency: The injection frequency can range from three times per week to once weekly or, for stable CKD patients, once every two weeks.
• Dose Adjustment: The protocol requires dose reduction if the Hb level is increasing too rapidly (e.g., greater than 2 g/dl in a 4-week period) or if the Hb concentration approaches or exceeds 12 g/dl.

Рекормон: Overview of Clinical Studies

---

Research in Anemia Associated with Chronic Kidney Disease (CKD)

Epoetin Beta (Рекормон) has been extensively studied in research populations with anemia related to CKD. This research includes numerous Randomized Controlled Trials (RCTs) and long-term observational studies. Researchers examined whether its use leads to stabilization of Hemoglobin (Hb) levels and assessed whether the studied groups had a lower frequency of Red Blood Cell (RBC) Transfusions compared to control groups. Studies also monitored patient-reported outcomes related to functional capacity and well-being.

Evidence suggests the treatment can stabilize blood counts. However, the optimal Hemoglobin target range remains a subject of ongoing scientific investigation. Long-term effects are not fully established regarding major clinical events, and research is ongoing to clarify specific outcomes associated with different treatment targets.

---

Research in Anemia Due to Chemotherapy

Clinical trials, including double-blind, placebo-controlled studies, were evaluated in adults with non-myeloid malignancies undergoing chemotherapy. Research explored whether the use of Epoetin Beta may lessen the need for RBC Transfusions during the treatment period. Findings describe patterns where transfusions were less frequently observed in the studied groups compared to placebo groups.

Certainty remains low for some long-term outcomes, and follow-up durations were limited in many studies. The research examined metrics like overall survival and disease progression, but findings were mixed regarding these endpoints.

---

Research in Specific Medical Situations

The treatment has also was studied for two other settings: autologous blood donation before major surgery and prevention of anemia in premature infants. In the pre-surgery setting, research examined outcomes related to patients' ability to donate their own blood, and findings indicate that fewer donor transfusions was observed in the studied groups. In premature infants, studies monitored the number of transfusions required, and findings indicate that fewer transfusions was observed in some studies, though some research suggested the overall effect size of this reduction is small.

Key Studies & References

1. Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients With Non-Myeloid Malignancies Receiving Chemotherapy
2. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation

Common questions about Рекормон (FAQ)

---

Q: Does it make you sleepy?

A: Official regulatory documents list drowsiness as a possible side effect of this medicine. Other related effects mentioned in the product information include dizziness and nervousness. Due to the potential for these effects, caution is generally advised before engaging in activities like driving or operating heavy machinery.

Q: Can I take it for migraines?

A: The official product information for some specific over-the-counter formulations of this medicine includes the treatment of migraine as an approved indication. Information on approved uses can be found on the specific product's packaging or official label.

Q: Is it safe long-term?

A: To minimize the risk of serious side effects, the regulatory label recommends using the lowest effective dose for the shortest duration necessary. Official product information emphasizes minimizing the duration of use and does not provide directions for extended use without the guidance of a healthcare professional.

Q: Can children 2 years old use it?

A: Use in children is covered by the official label, which provides dosing instructions based on weight or age, often covering children from 6 months up to 11 years. However, if the child is under 12 years old, the official over-the-counter label recommends that adults consult a doctor before administering the medicine.

Q: What happens if I drink alcohol with it?

A: The official label contains a specific Alcohol Warning. This warning notes that individuals who consume three or more alcoholic drinks daily are recommended to consult with a healthcare professional before taking this medicine. Combining the two may increase the risk of serious stomach bleeding.

Q: Is it safe to take during the third trimester of pregnancy?

A: Official regulatory documents contraindicate the use of this medicine during the last three months (the third trimester) of pregnancy. The label states this is a time when the medicine should not be used.

How to Store and Dispose of Recormon (Epoetin Beta)

Recormon must be stored under specific environmental and temperature controls to maintain its efficacy, as defined by regulatory labeling.

---

Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator between 2 C and 8 C.
Freezing	Do not freeze; discard if it has been frozen.
Protection	Keep in the original outer carton to protect from light.
Child Safety	Keep out of the sight and reach of children.

The product may be stored at a temperature not above 25 C for a maximum single period of three days for temporary use.

---

Disposal Instructions

Recormon is for single use. Any unused product or waste material must be disposed of according to local regulatory requirements. Used syringes and needles must be placed immediately in a puncture-resistant container (sharps container) and must not be disposed of in household waste or wastewater.